HIV-exposed uninfected infants in Zimbabwe

Insights into health outcomes in the pre-antiretroviral therapy era

Ceri Evans, Jean Hawes Humphrey, Robert Ntozini, Andrew J. Prendergast

Research output: Contribution to journalArticle

Abstract

The ZVITAMBO trial recruited 14,110 mother-infant pairs to a randomized controlled trial of vitamin A between 1997 and 2000, before the availability of antiretroviral therapy for HIV prophylaxis or treatment in Zimbabwe. The HIV status of mothers and infants was well characterized through 1-2 years of follow-up, leading to the largest cohort to date of HIV-exposed uninfected (HEU) infants (n = 3135), with a suitable comparison group of HIV-unexposed infants (n = 9510). Here, we draw on 10 years of published findings from the ZVITAMBO trial. HEU infants had increased morbidity compared to HIV-unexposed infants, with 50% more hospitalizations in the neonatal period and 30% more sick clinic visits during infancy, particularly for skin infections, lower respiratory tract infections, and oral thrush. HEU children had 3.9-fold and 2.0-fold higher mortality than HIV-unexposed children during the first and second years of life, respectively, most commonly due to acute respiratory infections, diarrhea/dysentery, malnutrition, sepsis, and meningitis. Infant morbidity and mortality were strongly related to maternal HIV disease severity, and increased morbidity remained until maternal CD4 counts were > 800 cells/μL. HEU infants were more likely to be premature and small-for-gestational age than HIV-unexposed infants, and had more postnatal growth failure. Here, we propose a conceptual framework to explain the increased risk of infectious morbidity, mortality, and growth failure among HEU infants, hypothesizing that immune activation and inflammation are key drivers of both infection susceptibility and growth failure. Future studies should further dissect the causes of infection susceptibility and growth failure anddetermine the impact of ART and cotrimoxazole on outcomes of this vulnerable group of infants in the current era.

Original languageEnglish (US)
Article number190
JournalFrontiers in Immunology
Volume7
Issue numberJUN
DOIs
StatePublished - Jun 6 2016

Fingerprint

Zimbabwe
HIV
Health
Therapeutics
Mothers
Morbidity
Growth
Respiratory Tract Infections
Infection
Oral Candidiasis
Dysentery
Mortality
Sulfamethoxazole Drug Combination Trimethoprim
Infant Mortality
CD4 Lymphocyte Count
Ambulatory Care
Vitamin A
Meningitis
Malnutrition
Gestational Age

Keywords

  • Africa
  • Breast-feeding
  • HIV exposure
  • Immune activation
  • Infant
  • Inflammation
  • Zimbabwe

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

HIV-exposed uninfected infants in Zimbabwe : Insights into health outcomes in the pre-antiretroviral therapy era. / Evans, Ceri; Humphrey, Jean Hawes; Ntozini, Robert; Prendergast, Andrew J.

In: Frontiers in Immunology, Vol. 7, No. JUN, 190, 06.06.2016.

Research output: Contribution to journalArticle

@article{44d794ce27fe447b82e926e11be769d6,
title = "HIV-exposed uninfected infants in Zimbabwe: Insights into health outcomes in the pre-antiretroviral therapy era",
abstract = "The ZVITAMBO trial recruited 14,110 mother-infant pairs to a randomized controlled trial of vitamin A between 1997 and 2000, before the availability of antiretroviral therapy for HIV prophylaxis or treatment in Zimbabwe. The HIV status of mothers and infants was well characterized through 1-2 years of follow-up, leading to the largest cohort to date of HIV-exposed uninfected (HEU) infants (n = 3135), with a suitable comparison group of HIV-unexposed infants (n = 9510). Here, we draw on 10 years of published findings from the ZVITAMBO trial. HEU infants had increased morbidity compared to HIV-unexposed infants, with 50{\%} more hospitalizations in the neonatal period and 30{\%} more sick clinic visits during infancy, particularly for skin infections, lower respiratory tract infections, and oral thrush. HEU children had 3.9-fold and 2.0-fold higher mortality than HIV-unexposed children during the first and second years of life, respectively, most commonly due to acute respiratory infections, diarrhea/dysentery, malnutrition, sepsis, and meningitis. Infant morbidity and mortality were strongly related to maternal HIV disease severity, and increased morbidity remained until maternal CD4 counts were > 800 cells/μL. HEU infants were more likely to be premature and small-for-gestational age than HIV-unexposed infants, and had more postnatal growth failure. Here, we propose a conceptual framework to explain the increased risk of infectious morbidity, mortality, and growth failure among HEU infants, hypothesizing that immune activation and inflammation are key drivers of both infection susceptibility and growth failure. Future studies should further dissect the causes of infection susceptibility and growth failure anddetermine the impact of ART and cotrimoxazole on outcomes of this vulnerable group of infants in the current era.",
keywords = "Africa, Breast-feeding, HIV exposure, Immune activation, Infant, Inflammation, Zimbabwe",
author = "Ceri Evans and Humphrey, {Jean Hawes} and Robert Ntozini and Prendergast, {Andrew J.}",
year = "2016",
month = "6",
day = "6",
doi = "10.3389/fimmu.2016.00190",
language = "English (US)",
volume = "7",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - HIV-exposed uninfected infants in Zimbabwe

T2 - Insights into health outcomes in the pre-antiretroviral therapy era

AU - Evans, Ceri

AU - Humphrey, Jean Hawes

AU - Ntozini, Robert

AU - Prendergast, Andrew J.

PY - 2016/6/6

Y1 - 2016/6/6

N2 - The ZVITAMBO trial recruited 14,110 mother-infant pairs to a randomized controlled trial of vitamin A between 1997 and 2000, before the availability of antiretroviral therapy for HIV prophylaxis or treatment in Zimbabwe. The HIV status of mothers and infants was well characterized through 1-2 years of follow-up, leading to the largest cohort to date of HIV-exposed uninfected (HEU) infants (n = 3135), with a suitable comparison group of HIV-unexposed infants (n = 9510). Here, we draw on 10 years of published findings from the ZVITAMBO trial. HEU infants had increased morbidity compared to HIV-unexposed infants, with 50% more hospitalizations in the neonatal period and 30% more sick clinic visits during infancy, particularly for skin infections, lower respiratory tract infections, and oral thrush. HEU children had 3.9-fold and 2.0-fold higher mortality than HIV-unexposed children during the first and second years of life, respectively, most commonly due to acute respiratory infections, diarrhea/dysentery, malnutrition, sepsis, and meningitis. Infant morbidity and mortality were strongly related to maternal HIV disease severity, and increased morbidity remained until maternal CD4 counts were > 800 cells/μL. HEU infants were more likely to be premature and small-for-gestational age than HIV-unexposed infants, and had more postnatal growth failure. Here, we propose a conceptual framework to explain the increased risk of infectious morbidity, mortality, and growth failure among HEU infants, hypothesizing that immune activation and inflammation are key drivers of both infection susceptibility and growth failure. Future studies should further dissect the causes of infection susceptibility and growth failure anddetermine the impact of ART and cotrimoxazole on outcomes of this vulnerable group of infants in the current era.

AB - The ZVITAMBO trial recruited 14,110 mother-infant pairs to a randomized controlled trial of vitamin A between 1997 and 2000, before the availability of antiretroviral therapy for HIV prophylaxis or treatment in Zimbabwe. The HIV status of mothers and infants was well characterized through 1-2 years of follow-up, leading to the largest cohort to date of HIV-exposed uninfected (HEU) infants (n = 3135), with a suitable comparison group of HIV-unexposed infants (n = 9510). Here, we draw on 10 years of published findings from the ZVITAMBO trial. HEU infants had increased morbidity compared to HIV-unexposed infants, with 50% more hospitalizations in the neonatal period and 30% more sick clinic visits during infancy, particularly for skin infections, lower respiratory tract infections, and oral thrush. HEU children had 3.9-fold and 2.0-fold higher mortality than HIV-unexposed children during the first and second years of life, respectively, most commonly due to acute respiratory infections, diarrhea/dysentery, malnutrition, sepsis, and meningitis. Infant morbidity and mortality were strongly related to maternal HIV disease severity, and increased morbidity remained until maternal CD4 counts were > 800 cells/μL. HEU infants were more likely to be premature and small-for-gestational age than HIV-unexposed infants, and had more postnatal growth failure. Here, we propose a conceptual framework to explain the increased risk of infectious morbidity, mortality, and growth failure among HEU infants, hypothesizing that immune activation and inflammation are key drivers of both infection susceptibility and growth failure. Future studies should further dissect the causes of infection susceptibility and growth failure anddetermine the impact of ART and cotrimoxazole on outcomes of this vulnerable group of infants in the current era.

KW - Africa

KW - Breast-feeding

KW - HIV exposure

KW - Immune activation

KW - Infant

KW - Inflammation

KW - Zimbabwe

UR - http://www.scopus.com/inward/record.url?scp=84977516762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977516762&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2016.00190

DO - 10.3389/fimmu.2016.00190

M3 - Article

VL - 7

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUN

M1 - 190

ER -